Literature DB >> 28122741

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.

Mark B Geyer1, Meier Hsu2, Sean M Devlin2, Martin S Tallman1, Dan Douer1, Jae H Park1,3.   

Abstract

Mesh：

Year:  2017        PMID： 28122741      PMCID： PMC5374292          DOI： 10.1182/blood-2016-11-749507

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  24 in total

1.  Population-based analyses in adult acute lymphoblastic leukemia.

Authors:  Gunnar Juliusson; Karin Karlsson; Helen Hallböök
Journal:  Blood       Date:  2010-08-12       Impact factor: 22.113

2.  Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Authors:  Marco Vignetti; Paola Fazi; Giuseppe Cimino; Giovanni Martinelli; Francesco Di Raimondo; Felicetto Ferrara; Giovanna Meloni; Achille Ambrosetti; Giovanni Quarta; Livio Pagano; Giovanna Rege-Cambrin; Loredana Elia; Raffaello Bertieri; Luciana Annino; Robin Foà; Michele Baccarani; Franco Mandelli
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

3.  Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008.

Authors:  Nina Toft; Kjeld Schmiegelow; Tobias W Klausen; Henrik Birgens
Journal:  Br J Haematol       Date:  2012-01-11       Impact factor: 6.998

4.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

5.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors:  R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

Review 6.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

Authors:  Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

7.  Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.

Authors:  Dan Douer; Ibrahim Aldoss; Matthew A Lunning; Patrick W Burke; Laleh Ramezani; Lisa Mark; Janice Vrona; Jae H Park; Martin S Tallman; Vassilios I Avramis; Vinod Pullarkat; Ann M Mohrbacher
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

8.  Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.

Authors:  Hagop M Kantarjian; Anthony S Stein; Ralf C Bargou; Carlos Grande Garcia; Richard A Larson; Matthias Stelljes; Nicola Gökbuget; Gerhard Zugmaier; Jonathan E Benjamin; Alicia Zhang; Catherine Jia; Max S Topp
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.860

9.  Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

Authors:  John M Storring; Mark D Minden; Susan Kao; Vikas Gupta; Andre C Schuh; Aaron D Schimmer; Karen W L Yee; Suzanne Kamel-Reid; Hong Chang; Jeffrey H Lipton; Hans A Messner; Wei Xu; Joseph M Brandwein
Journal:  Br J Haematol       Date:  2009-05-04       Impact factor: 6.998

10.  Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  Blood       Date:  2008-10-30       Impact factor: 22.113
View more
  15 in total

Review 1.  Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.

Authors:  Nicholas J Short; Hagop Kantarjian; Elias Jabbour; Farhad Ravandi
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

Review 2.  Treatment of Older Patients with Acute Lymphoblastic Leukaemia.

Authors:  Nicola Gökbuget
Journal:  Drugs Aging       Date:  2018-01       Impact factor: 3.923

3.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Authors:  Elias J Jabbour; Koji Sasaki; Farhad Ravandi; Nicholas J Short; Guillermo Garcia-Manero; Naval Daver; Tapan Kadia; Marina Konopleva; Nitin Jain; Jorge Cortes; Ghayas C Issa; Jovitta Jacob; Monica Kwari; Philip Thompson; Rebecca Garris; Naveen Pemmaraju; Musa Yilmaz; Susan M O'Brien; Hagop M Kantarjian
Journal:  Cancer       Date:  2019-04-15       Impact factor: 6.860

4.  Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?

Authors:  Marlise R Luskin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

5.  Correlates of common concerns in older cancer survivors of leukemia and lymphoma: results from the WHI LILAC study.

Authors:  Kah Poh Loh; Eric M McLaughlin; Jessica L Krok-Schoen; Oreofe O Odejide; Areej El-Jawahri; Lihong Qi; Aladdin H Shadyab; Lisa G Johnson; Electra D Paskett
Journal:  J Cancer Surviv       Date:  2022-08-18       Impact factor: 4.062

Review 6.  CAR T-Cell Therapy in the Older Person: Indications and Risks.

Authors:  Geoffrey Shouse; Alexey V Danilov; Andy Artz
Journal:  Curr Oncol Rep       Date:  2022-04-14       Impact factor: 5.945

7.  Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017.

Authors:  Koji Sasaki; Elias Jabbour; Nicholas J Short; Nitin Jain; Farhad Ravandi; Ching-Hon Pui; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2021-04-01       Impact factor: 13.265

Review 8.  Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.

Authors:  Bachar Samra; Elias Jabbour; Farhad Ravandi; Hagop Kantarjian; Nicholas J Short
Journal:  J Hematol Oncol       Date:  2020-06-05       Impact factor: 17.388

Review 9.  Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.

Authors:  Delong Liu; Juanjuan Zhao; Yongping Song; Xiaofeng Luo; Ting Yang
Journal:  J Hematol Oncol       Date:  2019-02-08       Impact factor: 17.388

Review 10.  Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.

Authors:  Nicholas J Short; Hagop Kantarjian; Elias Jabbour
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 12.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.